ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma

European Journal of Haematology

Volumn 84, Issue 6, 2010, Pages 474-483

  Offidani, Massimo ^a   Leoni, Pietro ^a   Corvatta, Laura ^b   Polloni, Claudia ^a   Gentili, Silvia ^a   Savini, Agnese ^a   Alesiani, Francesco ^b   Brunori, Marino ^b   Catarini, Massimo ^b   Visani, Giuseppe ^b   Samori, Arduino ^b   Burattini, Maurizio ^b   Centurioni, Riccardo ^b   Montanari, Mauro ^a   Fraticelli, Paolo ^b   Ruggieri, Miriana ^b   Falcioni, Sadia ^b   Galieni, Piero ^b  

^a OSPEDALI RIUNITI   (Italy)

^b Marche Myeloma Network (GEMaMM)   (Italy)

Author keywords

Autologous stem cell transplantation; Elderly; Multiple myeloma; Pegylated liposomal doxorubicin; Thalidomide

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THALIDOMIDE; WARFARIN;

AGED; ALOPECIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; CANCER REGRESSION; CD34 SELECTION; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DEATH; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERGLYCEMIA; INFECTION; INFECTION PREVENTION; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MELPHALAN; MULTIPLE MYELOMA; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77952596052     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01418.x     Document Type: Article

References (51)

1. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hemopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006 354: 1021 1030.
2. Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, Greipp PR. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oincology Group study not involving stem cell transplantation. Cancer 2006 106: 1958 1966.
3. Wang M, Delasalle K, Thomas S, Giralt S, Alexanian R. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 2006 108: abstract 403.
4. O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006 37: 731 737.
5. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007 92: 1399 1406.
6. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008 26: 5775 5782.
7. Cavo M, Tacchetti P, Patriarca P, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 2008 112: abstract 158.
8. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Francais du Myelome. N Engl J Med 1996 335: 91 7.
9. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003 348: 1875 1883.
10. Bladé J, Rosiñol L, Sureda A, et al Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005 106: 3755 3759.
11. Fermand JP, Katsahian S, Divine M, et al Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compareed with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005 23: 9227 9233.
12. Lenhoff S, Hjorth M, Turesson I, et al Nordic Myeloma Study Group. Intensive therapy for multiple myeloma in patients younger than 60 years: long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006 9: 1228 1233.
13. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007 25: 2434 2441.
14. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, Tricot G. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001 114: 600 607. (Pubitemid 32953638) (Pubitemid 32953638)
15. Reece DE, Bredeson C, Pérez WS, et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs ≥ 60 years of age. Bone Marrow Transplant 2003 32: 1135 1143.
16. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004 104: 3052 3057.
17. 2) supported by autologous stem cell transplantation is safe and effective in elderly (≥ 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006 37: 917 922.
18. Lenhoff S, Hjorth M, Westin J, et al Nordic Myeloma Study Group. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006 133: 389 396.
19. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006 108: 2159 2164.
20. San Miguel JF, Schlag R, Khuageva NK, et al VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 359: 906 917.
21. Besinger W, Jagannath S, Vescio R, et al. Phase II study of bortezomib (Velcade), cyclophosphamide (Cytoxan), thalidomide (Thalomid) and dexamethasone as first-line therapy for multiple myeloma. Blood 2008 112: abstract 94.
22. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008 111: 1101 1109.
23. Palumbo A, Falco P, Corradini P, et al GIMEMA-Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007 25: 4459 4465.
24. Richardson P, Lonial S, Jakubowiak A, Jagannath S, Raje SN, Avigan D, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood 2008 112: abstract 92.
25. Palumbo A, Bringhen S, Rossi D, Magarotto V, Di Raimondo F, Ria R, et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 2008 112: abstract 652.
26. Kumar S, Flinn IW, Noga SJ, Hari P, Rifkin RM, Scott Callander N, et al. Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multi-center EVOLUTION Study. Blood 2008 112: abstract 93.
27. Facon T, Mary JY, Hulin C, et al Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007 370: 1209 1218.
28. Palumbo A, Falco P, Gay F, Montefusco V, Crippa C, Patriarca F, et al. Bortezomib-doxorubicin-dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. Blood 2008 112: abstract 159.
29. Balducci L, Cohen HJ, Engstrom PF, et al National Comprehensive Cancer Network. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005 3: 572 590.
30. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT-European Group for Blood and Marrow Transplant. Br J Haematol 1998 102: 1115 1123.
31. Brenner H, Gondos A, Pulte D. Recent major improvement in ling-term survival of younger patients with multiple myeloma. Blood 2008 111: 2521 2526.
32. Palumbo A, Bringhen S, Caravita T, et al Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006 367: 825 831.
33. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomized phase 3 trial. Blood 2007 110: abstract 78.
34. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009 27: 3664 3670.
35. Wijermans P, Schaafsma M, van Norden Y, et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 study. Blood 2008 112: abstract 649.
36. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol 2008 26: abstract 8505.
37. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide inmproves survival in patients with multiple myeloma. Blood 2006 108: 3289 3294.
38. Morgan GJ, Jackson GH, Davies FE, et al. Maintenance thalidomide may improve progression free but not overall survival: results from the Myeloma IX maintenance randomization. Blood 2008 112: abstract 656.
39. Lockorst H, van der Holte B, Zweegman S, Von Dem Borne PA, Bos GMJ, Croockweit S, et al. Final analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine, dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple myeloma (MM). Blood 2008 112: abstract 157.
40. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009 27: 1788 1793.
41. Segeren CM, Sonneveld P, van der Holt B, et al Dutch-Belgian Hemato-Oncology Cooperative Study Group. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously utreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003 101: 2144 2151.
42. Durie BGM, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group Chemotherapy Trials. J Clin Oncol 2004 22: 1857 1863.
43. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR, Lacy MQ, Gastineau DA, Gertz MA. Realtionship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007 25: 4933 4937. (Pubitemid 350220425) (Pubitemid 350220425)
44. Kumar S, Dingli D, Dispenzieri A, Lacy M, Hayman SR, Buadi F, Rajkumar S, Litzow M, Gertz M. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant 2008 42: 259 264.
45. Bersagel PL. A kinder, gentler way: control of the proliferative tumor compartement, not cosmetic complete response, should be the goal of myeloma therapy. Leukemia 2008 22: 673 675.
46. Tricot G. Is more better in myeloma? Blood 2008 112: 3352.
47. Haessler J, Shaughnessy JD Jr., Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007 13: 7073 7079.
48. Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, Offord JR, Plevak MF, Therneau TM, Witzig TE. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001 97: 2522 2523.
49. Gastinne T, Leleu X, Duhamel A, et al Intergroupe Francophone du Myelome (IFM). Plasma cell growth fraction using ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol 2007 79: 297 304.
50. Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr., Anaissie E, Crowley J, Barlogie B. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008 22: 850 855.
51. Nair B, Zhou Y, Barlogie B, Sawyer J, Szymonifka J, Crowley J, Shaughnessy DY Jr. Only concomitant presence of cytogenetic abnormalities in randomly sampled bone marrow and in MRI-defined focal lesions imparts poor prognosis and is associated with gene expression profiling (GEP)-based high risk myeloma. Blood 2008 112: abstract 1691.